摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词
热门化合物HOT
  • 喹啉
  • 水杨醛
  • 二溴甲烷
  • 谷胱甘肽
  • L-乳酸
  • 苯巴比妥
  • 辣椒碱
  • 非那明
  • 百草枯
  • 联苯烯
首页 分子通 3-苄氧基苯乙酮

3-苄氧基苯乙酮 | 34068-01-4

物质功能分类

化学试剂 - 有机试剂 - 芳香酮

分子结构分类

有机化合物 - 有机氧化合物
中文名称
3-苄氧基苯乙酮
中文别名
3'-苯甲氧基苯乙酮
英文名称
1-[3-(phenylmethoxy)phenyl]ethan-1-one
英文别名
3'-benzyloxyacetophenone；1-(3-(benzyloxy)phenyl)ethanone；1-(3-(benzyloxy)phenyl)ethan-1-one；3-benzyloxyacetophenon；1-(3-phenylmethoxyphenyl)ethanone
3-苄氧基苯乙酮化学式
CAS
34068-01-4
化学式
C15H14O2
mdl
MFCD00026221
分子量
226.275
InChiKey
FGQMEAWGAUALJQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点：
    29-30 °C
  • 沸点：
    154°C/0.3mmHg(lit.)
  • 密度：
    1.0891 (rough estimate)
  • 溶解度：
    氯仿（微溶）、甲醇（微溶）
  • 最大波长(λmax)：
    305nm(MeOH)(lit.)
  • 稳定性/保质期：
    如果按照规定使用和储存，则不会发生分解，且目前没有发现已知的危险反应。应避免与氧化剂接触。

计算性质

  • 辛醇/水分配系数(LogP)：
    3.5
  • 重原子数：
    17
  • 可旋转键数：
    4
  • 环数：
    2.0
  • sp3杂化的碳原子比例：
    0.133
  • 拓扑面积：
    26.3
  • 氢给体数：
    0
  • 氢受体数：
    2

安全信息

  • 安全说明：
    S24/25
  • 海关编码：
    2914509090
  • 危险性防范说明：
    P261,P305+P351+P338
  • 危险性描述：
    H302,H315,H319,H335
  • 储存条件：
    请将贮藏器密封保存，并存放在阴凉、干燥处。同时，确保工作环境具备良好的通风或排气设施。

SDS

SDS：609d38ff8c8dad942265eeeaddaaafd0
查看
Name: 3-Benzyloxyacetophenone 97% Material Safety Data Sheet
Synonym: None Known
CAS: 34068-01-4
Section 1 - Chemical Product MSDS Name:3-Benzyloxyacetophenone 97% Material Safety Data Sheet
Synonym:None Known
Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
34068-01-4 3-Benzyloxyacetophenone 97% 251-816-0
Hazard Symbols: None Listed.
Risk Phrases: None Listed.
Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.
Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.
Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.
Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.
Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 34068-01-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.
Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H14O2
Molecular Weight: 226.10
Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported
Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 34068-01-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Benzyloxyacetophenone - Not listed by ACGIH, IARC, or NTP.
Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.
Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.
Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 34068-01-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 34068-01-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 34068-01-4 is not listed on the TSCA inventory.
It is for research and development use only.

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

反应信息

  • 作为反应物：
    描述：
    3-苄氧基苯乙酮 在 六氟异丙醇 、 C32H39BrMnN2O2P 、 potassium tert-butylate 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、3.0 MPa 条件下， 反应 16.0h， 以99%的产率得到(R)-1-(3-(benzyloxy)phenyl)ethanol
    参考文献：
    名称：
    基于卢替丁的手性钳式锰催化剂，用于酮的对映选择性加氢
    摘要：
    已经开发了一系列含有基于核苷的手性钳式配体的Mn I配合物，这些配合物具有模块化和可调的结构。该配合物在各种酮的氢化反应中显示出前所未有的高活性（高达9800 TON； TON =周转数），广泛的底物范围（81个实例），良好的官能团耐受性和出色的对映选择性（85-98％ee）。这些方面在稀土金属催化的氢化反应中很少见。该协议的实用性已在手性药物的多种关键中间体的不对称合成中得到证明。初步的机理研究表明，底物与催化剂相互作用的外层模式可能主导了催化作用。
    DOI：
    10.1002/anie.201814751
  • 作为产物：
    描述：
    3-苄氧基溴苯 在 正丁基锂 、 jones reagent 作用下， 生成 3-苄氧基苯乙酮
    参考文献：
    名称：
    Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1
    摘要：
    A novel series of PAI-1 inhibitors containing an oxadiazolidinedione moiety were identified by high through-put screening. Optimization of substituents by parallel synthesis and the iterative design toward understanding structure-activity relationship to improve potency are described. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI：
    10.1016/j.bmcl.2004.04.058
点击查看最新优质反应信息

文献信息

  • [EN] INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] DERIVES D'INDENE ET PROCEDE DE PREPARATION CORRESPONDANT
    申请人：KOREA RES INST CHEM TECH
    公开号：WO2005100303A1
    公开（公告）日：2005-10-27
    The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.
    式(I)的创新茚衍生物能够选择性地调节过氧化物酶体增殖物激活受体（PPARs）的活性，不会产生不良副作用，因此，它们对于治疗和预防由PPARs调节的疾病非常有用，即代谢综合征，如糖尿病、肥胖、动脉硬化、高脂血症、高胰岛素血症和高血压，以及炎症性疾病，如骨质疏松症、肝硬化和哮喘，以及癌症。
  • [EN] METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES NÉGATIFS (NAM) DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE ET UTILISATIONS DE CEUX-CI
    申请人：SANFORD BURNHAM MED RES INST
    公开号：WO2015191630A1
    公开（公告）日：2015-12-17
    Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    本文提供了小分子活性代谢型谷氨酸亚型-2和-3受体负向变构调节剂（NAMs），包括这些化合物的组合物，以及使用这些化合物和组合物的方法。
  • Synthesis of 2-Phenylbenzofuran Derivatives as Testosterone 5.ALPHA.-Reductase Inhibitor.
    作者：Koki ISHIBASHI、Katsuyoshi NAKAJIMA、Yuki SUGIOKA、Mitsuo SUGIYAMA、Takakazu HAMADA、Hiroyoshi HORIKOSHI、Takahide NISHI
    DOI：10.1248/cpb.47.226
    日期：——
    A series of 2-phenylbenzofuran derivatives with a carbamoyl, alkylamino, or alkyloxy group at the 5 or 6 position of the benzofuran ring were synthesized and evaluated for rat and human testosterone 5α-reductase inhibitory activities in vitro. Against rat enzyme, the carbamoyl derivatives had more potent inhibitory activities than the alkylamino or alkyloxy derivatives, and the 6-carbamoyl derivatives tended to be more potent than the 5-carbamoyl derivatives. Against human enzyme, the 6-substituted derivatives had more potent inhibitory activities than the 5-substituted derivatives. The 6-carbamoyl and 6-alkylamino derivatives tended to show stronger inhibitory activities against human type 1 enzyme than against type 2 enzyme, but they were not largely selective.
    一系列在苯并呋喃环的5或6位带有羰酰胺、烷基胺或烷氧基的2-苯基苯并呋喃衍生物被合成并评估了它们对大鼠和人体睾酮5α-还原酶的体外抑制活性。针对大鼠酶，羰酰胺衍生物的抑制活性比烷基胺或烷氧基衍生物更强，且6-羰酰胺衍生物往往比5-羰酰胺衍生物更有效。针对人体酶，6位取代的衍生物比5位取代的衍生物具有更强的抑制活性。6-羰酰胺和6-烷基胺衍生物往往对人类1型酶显示出比2型酶更强的抑制活性，但选择性不高。
  • Novel dimeric aryldiketo containing inhibitors of HIV-1 integrase: Effects of the phenyl substituent and the linker orientation
    作者：Li-Fan Zeng、Xiao-Hua Jiang、Tino Sanchez、Hu-Shan Zhang、Raveendra Dayam、Nouri Neamati、Ya-Qiu Long
    DOI：10.1016/j.bmc.2008.07.008
    日期：2008.8
    a further structure-activity relationship (SAR) study with respect to the substituent effect of the ADK and the dimerization with conformationally constrained linkers such as piperazine, 4-amino-piperidine, piperidin-4-ol, and trans-cyclohexan-1,4-diamine. The substituents on the phenyl ring as well as the spatial orientation of the two diketo units were observed to play important roles in the IN inhibitory
    芳基二酮酸（ADK）及其生物等排体是最有希望的HIV-1整合酶（IN）抑制剂。以前，我们设计了一系列ADK二聚体作为一类新的IN抑制剂，假设它们靶向IN活性位点上的两个二价金属离子。本文中，我们针对ADK的取代作用以及构象受限的连接基（例如哌嗪，4-氨基-哌啶，哌啶丁-4-醇和反式环己基-二聚体）的二聚化，提出了进一步的结构活性关系（SAR）研究。 1,4-二胺。观察到苯环上的取代基以及两个二酮单元的空间取向在IN抑制能力中起重要作用。疏水基团是在芳基环的3位上的最佳取代。哌嗪和4-氨基-哌啶连接基带来了疏水基团或卤素取代的ADK二聚体中最有效的类似物。对接研究表明，在3-苯环上的大量疏水取代和4-氨基-哌啶的连接体有利于采用一种活性构象，以实现与活性位点Mg（2+）和其中的关键残基E152的强相互作用。催化核心结构域。这项研究是我们先前关于含二聚体ADK的IN抑制剂的报告的重要扩展，为进
  • [EN] 2-METHYL-QUINAZOLINES<br/>[FR] 2-MÉTHYL-QUINAZOLINES
    申请人：BAYER PHARMA AG
    公开号：WO2018172250A1
    公开（公告）日：2018-09-27
    The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
    本发明描述了一般式(I)的2-甲基喹唑啉化合物，制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和组合物，以及用于制造药物组合物的该化合物的用途。一般式(I)的2-甲基取代喹唑啉化合物有效且选择性地抑制Ras-Sos相互作用，而不显著靶向EGFR受体。因此，它们对于治疗或预防疾病特别是高增殖性疾病，如癌症作为单一药剂或与其他活性成分组合使用是有用的。
查看更多

热门分子